ArticleAmerican journal of translational research2020
Doxorubicin restrains osteogenesis and promotes osteoclastogenesis in vitro.
Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Targeting cellular senescence mitigates chemotherapy-induced bone loss in young and aged mice.GeroScience · 2026Article
- Long-Term Clinical and Functional Outcomes after Intercalary Allograft Reconstruction for Oncologic Indications.Annals of surgical oncology · 2026Article
- Doxorubicin induces bone loss and modifies multiple cell populationsJournal of bone oncology · 2026Article
- Article
- Crosstalk between Wnt and bone morphogenetic protein signaling during osteogenic differentiation.World journal of stem cells · 2024Review
- Application of advanced biomaterials in photothermal therapy for malignant bone tumors.Biomaterials research · 2023Review
- Therapeutic Effects of Plant Extracts ofPlants (Basel, Switzerland) · 2023Article
- Resveratrol-Mediated Reversal of Doxorubicin-Induced Osteoclast Differentiation.International journal of molecular sciences · 2022Article
- Reversal of Doxorubicin-Induced Bone Loss and Mineralization by Supplementation of Resveratrol and MitoTEMPO in the Early Development ofNutrients · 2022Article
- IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer.Frontiers in oncology · 2022Article
- Chinese Herbal Medicine, Guilu Erxian Glue, as Alternative Medicine for Adverse Side Effects of Chemotherapy in Doxorubicin-Treated Cell and Mouse Models.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Effects of Soft Tissue Sarcoma and Doxorubicin on Bone Metabolism in Mice.In vivo (Athens, Greece)Article
- Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical evidence suggests that doxorubicin (DOX), as a chemotherapeutic drug, can induce severe bone damage in cancer patients. However, the effect of DOX on osteoporosis has not been fully elucidated. Therefore our study aims to investigate the effect and mechanism of DOX in osteoporosis. In our study, we co-cultured rat BMSCs with different concentrations of DOX solution, then the osteogenic differentiation markers and proliferation ability were analyzed. The results indicated that a certain concentration of the DOX solution may restrain the osteogenic differentiation of rat BMSCs by bmp-2/smads signalling pathway. Also, we found DOX promoted the receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced osteoclast formation. Our research explains excellently the induce-osteoporotic mechanism of DOX in vitro, which maybe contributing to the exploration of a new way to prevent osteoporosis caused by chemotherapy.
Indexed as
Identifiers
33042445PMC7540161What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.